VKH
IOVA icon

Virtu KCG Holdings’s Iovance Biotherapeutics IOVA Stock Holding History

Virtu KCG Holdings’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,072
Closed -$105K – 3179
2017
Q1 		$105K Sell
14,072
-1,953
-12% -$14.3K ﹤0.01% 2670
2016
Q4 		$111K Buy
16,025
+3,779
+31% +$26K ﹤0.01% 2876
2016
Q3 		$101K Buy
+12,246
New +$104K ﹤0.01% 2633
2015
Q4 		– Sell
-10,832
Closed -$62K – 3704
2015
Q3 		$62K Buy
+10,832
New +$84.4K ﹤0.01% 2953

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu KCG Holdings's IOVA Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Iovance Biotherapeutics (IOVA) in Q2 2017, closing a stake of 14,072 shares — an estimated $105K sold.

Virtu KCG Holdings first reported a position in IOVA in Q3 2015 and held it in 4 quarters. The position peaked at $111K in Q4 2016. 84 funds tracked by Wall St. Rank hold IOVA as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Iovance Biotherapeutics position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 14,072 Iovance Biotherapeutics shares in Q2 2017, an estimated $105K.
  • Virtu KCG Holdings first reported a position in Iovance Biotherapeutics in Q3 2015 and held it in 4 quarters.
  • Virtu KCG Holdings's Iovance Biotherapeutics position peaked at $111K in Q4 2016.
  • 84 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.